SOURCE: WayPoint Biomedical, Inc.

September 26, 2005 16:48 ET

WayPoint Biomedical Begins the Process to Become a Fully Reporting Company on the Bulletin Boards!

HUNTINGTON BEACH, CA -- (MARKET WIRE) -- September 26, 2005 -- WayPoint Biomedical, Inc. (OTC: WYPB) is currently in the process of interviewing SEC Certified Accounting and Auditing firms to represent WayPoint as they begin the process of becoming a fully reporting company.

WayPoint CEO, Dennis Shepherd, states, "It is my pleasure to announce that WayPoint intends to become a fully reporting company within the next three months. We believe this move will help enhance investor confidence and shareholder value, which is an integral component of WayPoint's overall goals." Mr. Shepherd further comments, "With innovative new products being launched and a previous release announcing a 300% increase in revenues, we believe our stock is undervalued."

About WayPoint Biomedical:

WayPoint Biomedical, Inc., a wholly owned subsidiary of WayPoint Biomedical Holdings, Inc. (OTC: WYPB), is an innovative biomedical technology firm, specializing in diagnostic tests and devices for screening and monitoring human health, fitness and environment. The Company develops and markets cutting-edge disposable rapid tests that offer both a preliminary diagnostic screen to specific conditions, along with a future path for consumers, medical providers, and first responders to follow regarding their health status or environmental condition. WayPoint's unique and affordable home-based and on-site tests are focused on detecting the cause of a disease or pathogen, as opposed to determining the symptom; becoming a part of the solution to help reverse the escalating cost of Healthcare. The Company's primary target sectors are the Over the Counter (OTC) Self-Testing Market, the Diagnostic Point of Care (POC) Testing Market, and the Homeland Security & Defense Market; three of the fastest growing areas in all of diagnostic medicine and science. For more information on WayPoint Biomedical visit,

Included in this release are certain "forward-looking'' statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding WayPoint's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to WayPoint's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. WayPoint Biomedical does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.

Contact Information

  • WayPoint Biomedical, Inc.
    Dennis Shepherd
    E-mail: Email Contact

    IR Firm: Corporate Awareness Professionals, Inc.
    Hank Zemla
    E-mail: Email Contact